Singapore
The new approach avoids malformations that are common in conventional methods, which produce particles that are ovoid in shape and result in poor flowability during manufacturing of medicines.
With the authorization by HSA, the VereCoV Detection Kit can be used directly by laboratories or hospitals to test patients for clinical diagnosis as an in-vitro diagnostic product (IVD).
iThermo reduces the need for manual temperature screening, and provides prompts where secondary checks can be carried out for feverish persons identified by the solution.
According to a recent BT report, the VereCoV detection kit is expected to be commercially available by Feb 1 this year.
New investors Alternate Ventures and KDV Capital, together with existing investor HealthXCapital also joined the round.
The startup develops non-invasive blood tests that achieve early cancer detection and improve treatment selection.